The most recent shutdown of the New England Compounding Center is apparently not the first time that the facility has been the target of regulators. A House panel convened in order to look into a recent meningitis outbreak stemming from the NECC’s distribution of contaminated steroid inspections has summarized how the Food and Drug Administration was recommending a production stoppage at the facility a decade ago. At that time, inspectors found conditions to be in line with a California compounder whose items apparently were tied to meningitis fatalities in 2001. The law impaired the FDA’s ability to shut down the Massachusetts plant, though, and the duty was passed to state officials. It should also be noted that, in 2002, two people at a hospital in Rochester, New York received an NECC steroid and later reported symptoms akin to a meningitis infection.
Follow this link to learn more.